DK1095275T3 - Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer - Google Patents

Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer

Info

Publication number
DK1095275T3
DK1095275T3 DK99941990T DK99941990T DK1095275T3 DK 1095275 T3 DK1095275 T3 DK 1095275T3 DK 99941990 T DK99941990 T DK 99941990T DK 99941990 T DK99941990 T DK 99941990T DK 1095275 T3 DK1095275 T3 DK 1095275T3
Authority
DK
Denmark
Prior art keywords
endogenous
protein
constitutively activated
orphan receptors
coupled orphan
Prior art date
Application number
DK99941990T
Other languages
Danish (da)
English (en)
Inventor
Derek T Chalmers
I-Lin Lin
Ruoping Chen
Dominic P Behan
Chen Liaw
Kevin Lowitz
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of DK1095275T3 publication Critical patent/DK1095275T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
DK99941990T 1998-07-31 1999-07-30 Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer DK1095275T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (1)

Publication Number Publication Date
DK1095275T3 true DK1095275T3 (da) 2009-09-28

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99941990T DK1095275T3 (da) 1998-07-31 1999-07-30 Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer

Country Status (13)

Country Link
EP (1) EP1095275B1 (xx)
JP (1) JP2002521681A (xx)
CN (1) CN1231762C (xx)
AT (1) ATE432472T1 (xx)
AU (1) AU751080B2 (xx)
CA (1) CA2338543C (xx)
DE (1) DE69940923D1 (xx)
DK (1) DK1095275T3 (xx)
IL (1) IL140858A0 (xx)
MX (1) MXPA01001176A (xx)
NO (1) NO20010509L (xx)
NZ (1) NZ509429A (xx)
WO (1) WO2000006597A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
JP2003532057A (ja) 2000-04-07 2003-10-28 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内因性の、構成的に活性化される既知gタンパク質−共役受容体
WO2003078602A2 (en) * 2002-03-15 2003-09-25 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003081256A2 (en) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
WO2004015422A2 (en) * 2002-08-05 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
EP1578798A1 (en) * 2002-12-20 2005-09-28 7TM Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507518A (ja) * 1995-06-07 1999-07-06 プレーシス ファーマスーティカルズ インコーポレイテッド G蛋白質とカップルしたレセプターのアゴニスト及びアンタゴニストの機能的バイオアッセイ
WO1997011159A1 (en) * 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
ATE423313T1 (de) * 1997-04-14 2009-03-15 Arena Pharm Inc Methode zum identifizieren von modulatoren der zelloberflächenmembranrezeptoren,nützlich zur behandlung von krankheiten

Also Published As

Publication number Publication date
WO2000006597A9 (en) 2000-07-13
MXPA01001176A (es) 2005-07-25
WO2000006597A2 (en) 2000-02-10
JP2002521681A (ja) 2002-07-16
NO20010509L (no) 2001-03-19
CN1231762C (zh) 2005-12-14
AU751080B2 (en) 2002-08-08
CA2338543C (en) 2009-12-29
NZ509429A (en) 2002-06-28
EP1095275B1 (en) 2009-05-27
DE69940923D1 (de) 2009-07-09
AU5545999A (en) 2000-02-21
WO2000006597A3 (en) 2000-05-18
EP1095275A2 (en) 2001-05-02
CN1323396A (zh) 2001-11-21
ATE432472T1 (de) 2009-06-15
CA2338543A1 (en) 2000-02-10
NO20010509D0 (no) 2001-01-30
IL140858A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
ATE344241T1 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosine kinasesn, insbesondere von raf kinasen
ATE215369T1 (de) Carbazolanaloge als selektive beta3-adrenergische agonisten
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
ITMI991964A0 (it) Derivati benzimidazolonici aventi affinita' mista per i recettori di s erotonina e dopamina
DE60136571D1 (de) Guanidinobenzamide als mc4-r agonisten
SE9704836D0 (sv) Novel receptor
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
DE69133135D1 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
ES2162231T3 (es) Nuevos derivados de n-(arilsulfonil)aminoacidos que tienen afinidad con los receptores de bradicinina.
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
BR0116698A (pt) Composto de modafinila e misturas de ciclodextrina, uso e método de obtenção dos mesmos
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
DK1095275T3 (da) Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer
BR0318631A (pt) os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo
DK0862627T3 (da) Neuropeptid Y-Y5 receptor
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.